Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 201–300 of 1,000
Regulatory SNPs in complex diseases: their identification and functional validation
Prokunina‐Olsson, L., & Alarcón-Riquelme, M. E. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007690 · Cited by 119
Warren, A. J., Bravo, J., Williams, R. L., & Rabbitts, T. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.3004 · Cited by 118
Molecular and Clinical Evaluation of a Patient Hemizygous for TIGR/MYOC
Wiggs, J. L., & Vollrath, D. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.11.1674 · Cited by 107
Pencovich, N., Jaschek, R., Tanay, A., & Groner, Y. (2011) · Blood · doi:10.1182/blood-2010-07-295113 · Cited by 103
Yang, F., Long, N., Anekpuritanang, T., Bottomly, D., Savage, J. C., Lee, T. L., Solis-Ruiz, J. M., Borate, U., Wilmot, B., Tognon, C. E., et al. (2021) · Blood · doi:10.1182/blood.2021011354 · Cited by 111
Transcriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“In addition, RUNX1 point mutations were reported in sporadic and familial myeloid leukemia (Osato et al., 1999; Song et al., 1999).”
BackgroundBödör, C., Renneville, A., Smith, M., Charazac, A., Iqbal, S., Etancelin, P., Cavenagh, J. D., Barnett, M. J., Kramarzová, K. Š., Krishnan, B., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.054361 · Cited by 106
Takenouchi, T., Kosaki, R., Niizuma, T., Hata, K., & Kosaki, K. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37275 · Cited by 102
Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia
Antony‐Debré, I., Manchev, V. T., Balayn, N., Bluteau, D., Tomowiak, C., Legrand, C., Langlois, T., Bawa, O., Tosca, L., Tachdjian, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-585513 · Cited by 111
Accommodating haploinsufficient tumour suppressor genes in Knudson's model
Cook, W. D., & McCaw, B. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203653 · Cited by 126
“There are reports in the literature for several tsg, namely Nf1 (Jacks et al., 1994), p27Kip1 (Pietenpol et al., 1995), Msh2 (de Wind et al., 1998), Pten (Podsypanina et al., 1999), Tsc2 (Kobayashi et al., 1999), CBFA2 (Song et al., 1999) and p53 (Nigro et al., 1989; Mulligan et al., 1990; Davido et al., 1991; Sedlace…”
BackgroundInfluentialHeller, P. G., Glembotsky, A. C., Gandhi, M. J., Cummings, C. L., Pirola, C. J., Marta, R. F., Kornblihtt, L. I., Drachman, J. G., & Molinas, F. C. (2005) · Blood · doi:10.1182/blood-2005-01-0050 · Cited by 104
Mangan, J. K., & Speck, N. A. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.80 · Cited by 102
Self-citationHuman phenotypes associated with GATA-1 mutations
Ciovacco, W. A., Raskind, W. H., & Kacena, M. A. (2008) · Gene · doi:10.1016/j.gene.2008.09.018 · Cited by 108
“Runx-1 knockout mice are thrombocytopenic due to a halt in MK differentiation, and constitutional Runx-1 haploinsufficiency in humans leads to thrombocytopenia and the aforementioned increased rates of myeloid leukemia (Ichikawa et al., 2004, Song et al., 1999).”
BackgroundGenetics of familial forms of thrombocytopenia
Balduini, C. L., & Savoia, A. (2012) · Human Genetics · doi:10.1007/s00439-012-1215-x · Cited by 102
“FPD/AML is associated with alterations of RUNX1, a gene encoding for a subunit of the core binding factor (CBF) transcription complex (Song et al. 1999).”
BackgroundDeletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
Ebert, B. L. (2009) · Leukemia · doi:10.1038/leu.2009.53 · Cited by 114
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 112
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)
Brown, A. L., Hahn, C. N., & Scott, H. S. (2020) · Blood · doi:10.1182/blood.2019000937 · Cited by 106
Churpek, J. E., Lorenz, R., Nedumgottil, S., Onel, K., Olopade, O. I., Sorrell, A., Owen, C., Bertuch, A. A., & Godley, L. A. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.701738 · Cited by 102
Steensma, D. P. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0140-3 · Cited by 102
“A prodrome of thrombocytopenia preceding development of MDS or AML characterizes germline mutations in the RUNX1 (CBAF2, AML1) transcription factor, but the newly described GATA2 germline mutations that also increase risk for subsequent MDS development have no prodrome [39, 40].”
BackgroundBéri‐Dexheimer, M., Latger‐Cannard, V., Philippe, C., Bonnet, C., Chambon, P., Roth, V., Gregoire, M., Bordigoni, P., Lecompte, T., Leheup, B., et al. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.89 · Cited by 103
AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia.
Niini, T., Kanerva, J. A., Vettenranta, K. K., Saarinen‐Pihkala, U. M., & Knuutila, S. (2000) · PubMed · Cited by 109
Lai, F., Godley, L. A., Joslin, J. M., Fernald, A. A., Liu, J., Espinosa, R., Zhao, N., Pamintuan, L., Till, B. G., Larson, R. A., et al. (2001) · Genomics · doi:10.1006/geno.2000.6414 · Cited by 101
Jongmans, M. C. J., Kuiper, R. P., Carmichael, C., Wilkins, E., Dors, N., Carmagnac, A., Meeteren, A. Y. N. S., Li, X., Stankovic, M., Kamping, E. J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.210 · Cited by 97
Germline ETV6 mutations and predisposition to hematological malignancies
Feurstein, S. K., & Godley, L. A. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2259-4 · Cited by 107
“Germline mutations in both PAX5 and RUNX1 are known as leukemia predisposition syndromes [30, 40].”
BackgroundInherited thrombocytopenias: history, advances and perspectives
Nurden, A. T., & Nurden, P. (2020) · Haematologica · doi:10.3324/haematol.2019.233197 · Cited by 102
Tóthová, Z., Valton, A.-L., Gorelov, R. A., Vallurupalli, M., Krill-Burger, J. M., Holmes, A. L., Landers, C. C., Haydu, J. E., Małolepsza, E., Hartigan, C. R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.142149 · Cited by 98
“Engraftment and clonal expansion of Tet2-mutant cells were confirmed by fluorescent protein reporter expression and next-generation sequencing (37), and were not associated with an overt phenotype (Fig.”
Emerling, B. M., Bonifas, J. M., Kratz, C. P., Donovan, S., Taylor, B. R., Green, E. D., Beau, M. M. L., & Shannon, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205615 · Cited by 96
“Interestingly, germline mutations of RUNX1 (also known as AML1 or CBFA2) were recently found to cause a familial platelet disorder that is associated with a predisposition to myeloid leukemia (Song et al., 1999).”
BackgroundPrognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics
Gaidzik, V. I., & Döhner, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.005 · Cited by 110
Greene, M. E., Mundschau, G., Wechsler, J. B., McDevitt, M. A., Gamis, A. S., Karp, J. E., Gurbuxani, S. K., Arceci, R. J., & Crispino, J. D. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2003.08.001 · Cited by 107
Seifert, B. A., O'Daniel, J. M., Amin, K., Marchuk, D. S., Patel, N. M., Parker, J. S., Hoyle, A. P., Mose, L. E., Marron, A., Hayward, M. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0015 · Cited by 95
The core-binding factor leukemias: lessons learned from murine models
Downing, J. R. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00018-7 · Cited by 106
Imai, Y., Kurokawa, M., Yamaguchi, Y., Izutsu, K., Nitta, E., Mitani, K., Satake, M., Noda, T., Ito, Y., & Hirai, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1033-1043.2004 · Cited by 92
“Furthermore, point mutations in the Runt domain of the AML1 gene were found in patients with AML (31, 33), familial platelet disorder with predisposition to AML (35), or myelodysplastic syndrome (9).”
BackgroundDeguchi, K., & Gilliland, D. G. (2002) · Leukemia · doi:10.1038/sj.leu.2402500 · Cited by 106
Self-citationRUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM)
Schlegelberger, B., & Heller, P. G. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.04.006 · Cited by 98
“Song et al. (1999) were the first to describe heterozygous germline RUNX1 mutations in six families, each carrying a different mutation.”
BackgroundHigh frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML
Simon, L., Spinella, J.-F., Yao, C., Lavallée, V., Boivin, I., Boucher, G., Audemard, E. O., Bordeleau, M.-È., Lemieux, S., Hébert, J., et al. (2020) · Blood · doi:10.1182/blood.2019003357 · Cited by 93
Focus on myeloproliferative diseases and myelodysplastic syndromes
Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 93
Dayyani, F., Wang, J., Yeh, J.-R. J., Ahn, E.-Y. E., Tobey, E. M., Zhang, D., Bernstein, I. D., Peterson, R. T., & Sweetser, D. A. (2008) · Blood · doi:10.1182/blood-2007-07-103291 · Cited by 100
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations
Antony‐Debré, I., Bluteau, D., Itzykson, R., Baccini, V., Renneville, A., Boehlen, F., Morabito, M., Droin, N. M., Deswarte, C., Chang, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422352 · Cited by 91
Sakurai, M., Kunimoto, H., Watanabe, N., Fukuchi, Y., Yuasa, S., Yamazaki, S., Nishimura, T., Sadahira, K., Fukuda, K., Okano, H., et al. (2014) · Leukemia · doi:10.1038/leu.2014.136 · Cited by 96
Dinardo, C. D., Bannon, S. A., Routbort, M. J., Franklin, A. R. K., Mork, M. E., Armanios, M. Y., Mace, E. M., Orange, J. S., Jeff‐Eke, M., Churpek, J. E., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.04.001 · Cited by 93
Myeloid neoplasms with germline DDX41 mutation
Cheah, J., Hahn, C. N., Hiwase, D., Scott, H. S., & Brown, A. L. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2260-y · Cited by 90
AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis
Ichikawa, M., Goyama, S., Asai, T., Kawazu, M., Nakagawa, M., Takeshita, M., Chiba, S., Ogawa, S., & Kurokawa, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4402 · Cited by 83
RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia
Choi, A., Illendula, A., Pulikkan, J. A., Roderick, J. E., Tesell, J., Yu, J., Hermance, N. M., Zhu, L. J., Castilla, L. H., Bushweller, J. H., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775536 · Cited by 93
“Germline RUNX1 mutations are associated with familial platelet disorder (FPD) and increased risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).(5,6) RUNX1 and CBFβ are the most frequent targets of chromosomal translocation in AML, resulting in the generation of novel AML1-ETO and CBFβ-MYH11 fusion…”
Self-citationEdwards, H. J., Xie, C., LaFiura, K. M., Dombkowski, A. A., Buck, S. A., Boerner, J. L., Taub, J. W., Matherly, L. H., & Ge, Y. (2009) · Blood · doi:10.1182/blood-2008-09-179812 · Cited by 91
Helbling, D., Mueller, B. U., Timchenko, N. A., Hagemeijer, A., Jotterand, M., Meyer‐Monard, S., Lister, A. T., Rowley, J. D., Huegli, B., Fey, M. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404731101 · Cited by 100
The cytogenetics of myelodysplastic syndromes
Olney, H. J., & Beau, M. M. L. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0151 · Cited by 89
Sun, L., Gorospe, J. R., Hoffman, E. P., & Rao, A. K. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02271.x · Cited by 88
Recurrent CDC25C mutations drive malignant transformation in FPD/AML
Yoshimi, A., Toya, T., Kawazu, M., Ueno, T., Tsukamoto, A., Iizuka, H., Nakagawa, M. M., Nannya, Y., Arai, S., Harada, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms5770 · Cited by 88
Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
Seif, A. E. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.04.005 · Cited by 104
Pratap, J., Imbalzano, K. M., Underwood, J. M., Cohet, N., Gokul, K. D., Akech, J., van Wijnen, A. J., Stein, J. L., Imbalzano, A. N., Nickerson, J. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1471 · Cited by 88
“Runx1 and Runx3 mutations promote leukemia and gastric cancers, respectively (8, 9).”
BackgroundDown syndrome and leukemia: insights into leukemogenesis and translational targets
Mateos, M. K., Barbaric, D., Byatt, S.-A., Sutton, R., & Marshall, G. M. (2015) · PubMed Central · doi:10.25405/ncl.34316163 · Cited by 105
Linkage between the mechanisms of thrombocytopenia and thrombopoiesis
Eto, K., & Kunishima, S. (2016) · Blood · doi:10.1182/blood-2015-07-607903 · Cited by 96
“Familial platelet disorder with predisposition to acute myeloid leukemia is caused by mutations in RUNX1, the gene encoding the a subunit of the CBF transcription complex.(61) CBF is essential for the establishment of definitive hematopoiesis and for regulation of the maintenance, proliferation, and differentiation of…”
BackgroundCore binding factor genes and human leukemia.
Hart, S., & Foroni, L. (2002) · PubMed · Cited by 104
Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development.
Huang, H., Yu, M., Akie, T. E., Moran, T. B., Woo, A. J., Tu, N., Waldon, Z., Lin, Y. Y., Steen, H., & Cantor, A. B. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00090-09 · Cited by 87
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia (40, 48).”
BackgroundClinical utility of next-generation sequencing for inherited bone marrow failure syndromes
Muramatsu, H., Okuno, Y., Yoshida, K., Shiraishi, Y., Doisaki, S., Narita, A., Sakaguchi, H., Kawashima, N., Wang, X., Xu, Y., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.197 · Cited by 90
Zebrafish a genetic model for vertebrate organogenesis and human disorders
Paw, B. H. (2003) · Frontiers in bioscience · doi:10.2741/1092 · Cited by 100
“In addition, point mutations in RUNX1 have been described in myelodysplasias (119) and haploinsufficiency of RUNX1 can cause familial thrombocytopenia (120).”
BackgroundJalagadugula, G. S., Mao, G., Kaur, G., Goldfinger, L. E., Dhanasekaran, D. N., & Rao, A. K. (2010) · Blood · doi:10.1182/blood-2010-06-289850 · Cited by 90
Runx1/AML1 in Normal and Abnormal Hematopoiesis
Yamagata, T., Maki, K., & Mitani, K. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05075 · Cited by 93
Leukemic transformation of polycythemia vera: A single center study of 23 patients
Passamonti, F., Rumi, E., Arcaini, L., Castagnola, C., Lunghi, M., Bernasconi, P., Giovanni Della Porta, M., Columbo, N., Pascutto, C., Cazzola, M., et al. (2005) · Cancer · doi:10.1002/cncr.21297 · Cited by 85
Emberger syndrome—Primary lymphedema with myelodysplasia: Report of seven new cases
Mansour, S., Connell, F., Steward, C. G., Østergaard, P., Brice, G. W., Smithson, S., Lunt, P. W., Jeffery, S., Dokal, I. S., Vulliamy, T., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33445 · Cited by 88
“To date, analysis of families with MDS/AML has lead to the detection of two pathogenic genes; CEBPA (CCAAT/Enhancerbinding protein, alpha) and RUNX1 (Runt-related transcription factor/AML 1 gene; AML1/core-binding factor, runt domain, alpha subunit 2; CBFA2) [Song et al., 1999; Smith et al., 2004].”
BackgroundKanagal-Shamanna, R., Loghavi, S., DiNardo, C. D., Medeiros, L. J., Garcia-Manero, G., Jabbour, E., Routbort, M. J., Luthra, R., Bueso-Ramos, C. E., & Khoury, J. D. (2017) · Haematologica · doi:10.3324/haematol.2017.167726 · Cited by 84
The molecular pathogenesis of acute myeloid leukemia
Steffen, B., Müller‐Tidow, C., Schwäble, J., Berdel, W. E., & Serve, H. L. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.012 · Cited by 111
B-lineage transcription factors and cooperating gene lesions required for leukemia development
Tijchon, E. J. H., Havinga, J., van Leeuwen, F. N., & Scheijen, B. (2012) · Leukemia · doi:10.1038/leu.2012.293 · Cited by 97
Inherited thrombocytopenias: an updated guide for clinicians
Pecci, A., & Balduini, C. L. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100784 · Cited by 86
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
Larizza, L., Magnani, I., & Beghini, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400007565 · Cited by 91
“First, germline mutations in AML1 associated with the FPD/AML syndrome (MIM# 301699) require second mutations later in life for development of AML [30] and second, murine models where a conditional allele has been utilized to achieve the expression of the AML1/ ETO fusion protein in adult hematopoietic progenitors do…”
BackgroundCommon features of megakaryocytes and hematopoietic stem cells: What's the connection?
Huang, H., & Cantor, A. B. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22184 · Cited by 94
“In humans, heterozygous Runx-1 germline mutations cause Familial Platelet Disorder with Propensity to Develop AML (FPD/AML), a rare autosomal dominant disorder characterized by thrombocytopenia, platelet dysfunction, and markedly elevated risk for Myelodysplastic syndrome (MDS) and leukemia (median incidence 35%) [Son…”
BackgroundBiggs, J. R., Peterson, L. F., Zhang, Y., Kraft, A. S., & Zhang, D.-E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00597-06 · Cited by 83
“The association of AML1 with blood cell development is shown by the disruption of the AML1 gene through multiple chromosomal translocations, deletions, point mutations, or amplification in approximately 30% of human myeloid leukemias and myelodysplastic syndrome patients and a significant number of lymphoid leukemia p…”
BackgroundIsoform-Specific Potentiation of Stem and Progenitor Cell Engraftment by AML1/RUNX1
Tsuzuki, S., Hong, D., Gupta, R., Matsuo, K., Seto, M., & Enver, T. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040172 · Cited by 83
“Aml1 is itself a case in point [54], and GATA-2 [55,56], PU1 [57], and OCT4 [58] provide additional examples.”
BackgroundMarked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia
Holme, H., Hossain, U., Kirwan, M., Walne, A. J., Vulliamy, T., & Dokal, I. S. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09136.x · Cited by 83
Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia
Bloom, M., Maciaszek, J. L., Clark, M. E., Pui, C., & Nichols, K. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1685866 · Cited by 89
“iants predicted to result in RUNX1 haploinsufficiency [82].”
BackgroundShinawi, M. S., Erez, A., Shardy, D. L., Lee, B., Naeem, R. C., Weissenberger, G., Chinault, A. C., Cheung, S. W., & Plon, S. E. (2008) · Blood · doi:10.1182/blood-2008-01-135970 · Cited by 86
Ganly, P. S., Walker, L. C., & Morris, C. M. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000139611 · Cited by 87
“Mutations were also found in 0/6 patients with MDS, 1/8 with blast crisis CML and 1/37 with ALL [37].”
BackgroundInfluentialGenotyping and phenotyping of platelet function disorders
Watson, S. P., Lowe, G., Lordkipanidzé, M., & Morgan, N. V. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12199 · Cited by 81
Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk
Sud, A., Chattopadhyay, S., Thomsen, H., Sundquist, K., Sundquist, J., Houlston, R. S., & Hemminki, K. (2019) · Blood · doi:10.1182/blood.2019001362 · Cited by 82
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?
Bresnick, E. H., Jung, M. M., & Katsumura, K. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002953 · Cited by 83
Rudelius, M., Weinberg, O. K., Niemeyer, C. M., Shimamura, A., & Calvo, K. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03447-9 · Cited by 89
“Autosomal dominant germline heterozygous mutations in RUNX1 were discovered in patients with familial platelet disorder with propensity to develop acute myeloid leukemia in 1999 [27].”
BackgroundSrivastava, M., Montagna, C., Leighton, X., Glasman, M., Naga, S., Eidelman, O., Ried, T., & Pollard, H. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235927100 · Cited by 81
Runx2 in human breast carcinoma: its potential roles in cancer progression
Onodera, Y., Miki, Y., Suzuki, T., Takagi, K., Akahira, J., Sakyu, T., Watanabe, M., Inoue, S., Ishida, T., Ohuchi, N., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01742.x · Cited by 83
RUNX1 Mutations in Inherited and Sporadic Leukemia
Bellissimo, D. C., & Speck, N. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00111 · Cited by 84
“INHERITED MUTATIONS IN RUNX1 Inherited mono-allelic RUNX1 mutations are associated with “familial platelet disorder with predisposition to AML” (FPD/AML) (Song et al., 1999).”
BackgroundSelf-citationRunx1Protects Hematopoietic Stem/Progenitor Cells from Oncogenic Insult
Motoda, L., Osato, M., Yamashita, N., Jacob, B., Chen, L. Q., Yanagida, M., Ida, H., Wee, H., Sun, A. X., Taniuchi, I., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0061 · Cited by 82
Thrombocytopenia in the newborn
Roberts, I. A. G., & Murray, N. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200302000-00004 · Cited by 84
Myelodysplastic Syndrome in Children and Adolescents
Niemeyer, C. M., & Baumann, I. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.10.006 · Cited by 89
Sun, L., Mao, G., & Rao, A. K. (2004) · Blood · doi:10.1182/blood-2003-07-2299 · Cited by 79
2014 Jeffrey M. Hoeg Award Lecture: Transcriptional Control of Monocyte Development
Zhu, Y. P., Thomas, G. D., & Hedrick, C. C. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.304054 · Cited by 91
“Similarly, in humans, haploinsufficiency of RUNX1 is associated with increased myeloid progenitors.(103) RUNX1 binds to the promoter region of PU.”
BackgroundConnelly, J. P., Kwon, E. M., Gao, Y., Trivedi, N. S., Elkahloun, A. G., Horwitz, M. S., Cheng, L., & Liu, P. (2014) · Blood · doi:10.1182/blood-2014-01-550525 · Cited by 82
Sakakura, C., Hagiwara, A., Miyagawa, K., Nakashima, S., Yoshikawa, T., Kin, S., Nakase, Y., Ito, K., Yamagishi, H., Yazumi, S., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20551 · Cited by 87
Gene Targeting Reveals a Crucial Role forMTG8 in the Gut
Calabi, F., Pannell, R., & Pavloska, G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5658-5666.2001 · Cited by 89
“Mouse runx1 has been shown to be essential for definitive hemopoiesis (23, 37) and haploinsufficiency at runx1 in humans is associated with diserythropoiesis and an increased risk of AML (32).”
BackgroundHereditary Predispositions to Myelodysplastic Syndrome
Bannon, S. A., & Dinardo, C. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060838 · Cited by 76
“Familial platelet disorder with propensity to myeloid malignancies RUNX1 AD MDS/AML/T-cell ALL Thrombocytopenia, bleeding propensity, aspirin-like platelet dysfunction [3]”
BackgroundAsou, N. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00003-3 · Cited by 80
“[247] and pedigrees A1 and A2 were reported by Michaud et al.”
BackgroundInfluentialFeng, J., Iwama, A., Satake, M., & Kohu, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07632.x · Cited by 79
“In familial platelet disorder, a haploinsufficiency of RUNX1 results in reduction of endogenous RUNX1 protein (Song et al, 1999).”
BackgroundInherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia
Galera, P. K., Dulau‐Florea, A., & Calvo, K. R. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12999 · Cited by 79
Roche‐Lestienne, C., Deluche, L., Corm, S., Tigaud, I., Joha, S., Philippe, N., Geffroy, S., Laï, J., Nicolini, F. E., & Preudhomme, C. (2008) · Blood · doi:10.1182/blood-2007-07-102533 · Cited by 80
Kaur, G., Jalagadugula, G. S., Mao, G., & Rao, A. K. (2010) · Blood · doi:10.1182/blood-2009-04-214601 · Cited by 84
AML1 gene over-expression in childhood acute lymphoblastic leukemia
Mikhail, F., Serry, K. A., Hatem, N., Mourad, Z., Farawela, H., Elkaffash, D. M., Coignet, L., & Nucifora, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402399 · Cited by 83
Paulsson, K. M., Békássy, A. N., Olofsson, T., Mitelman, F., Johansson, B., & Panagopoulos, I. (2005) · Leukemia · doi:10.1038/sj.leu.2404076 · Cited by 79
A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes
Scollon, S., Anglin, A. K., Thomas, M. H., Turner, J. T., & Schneider, K. W. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0077-8 · Cited by 76
Posttranslational modifications of RUNX1 as potential anticancer targets
Goyama, S., Huang, G., Kurokawa, M., & Mulloy, J. C. (2014) · Oncogene · doi:10.1038/onc.2014.305 · Cited by 75
Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus.
Alarcón-Riquelme, M. E. (2004) · Arthritis Research · doi:10.1186/ar1203 · Cited by 74
“described for RUNX1 haploinsufficiency, an individual with the mutation had rheumatoid arthritis [23].”
BackgroundHematopoietic transcription factor mutations: important players in inherited platelet defects
Songdej, N., & Rao, A. K. (2017) · Blood · doi:10.1182/blood-2016-11-709881 · Cited by 75
“In patients with RUNX1 mutations, MKs cultured from stem cells also demonstrate defects in differentiation and polyploidization.(17,24) This has been associated with dysregulated nonmuscle myosin IIA (MYH9) and IIB (MYH10) expression, with impaired MYH10 silencing and reduced MYL9 and MYH9 expression.”
BackgroundThe Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia
Gianni, F., Belver, L., & Ferrando, A. A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035246 · Cited by 83
“Germline heterozygous mutations in RUNX1 are found in families affected with FPDMM (platelet disorder, familial, with associated myeloid malignancy; OMIM ID #601399), a leukemia predisposition syndrome characterized by a moderate decrease in platelet numbers and an increased risk of acute myeloid leukemia (Song et al.…”
Background
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.